← Browse by Condition
Medical Condition

breast neoplasm female

Total Trials
4
Recruiting Now
4
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for breast neoplasm female sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — breast neoplasm female Clinical Trials

How many clinical trials are currently recruiting for breast neoplasm female?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for breast neoplasm female, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for breast neoplasm female?
breast neoplasm female research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a breast neoplasm female clinical trial?
Eligibility criteria for breast neoplasm female trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Georgetown University 1 trial
Ahmet Yesildag 1 trial
Danish Breast Cancer Cooperative Group 1 trial
University of Illinois at Chicago 1 trial

Recruiting Clinical Trials

NCT06892275
Recruiting

The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI

Enrollment
80 pts
Location
United States
Sponsor
Georgetown University
View Trial →
NCT07465523
Recruiting

A Novel Approach in the Evaluation of Breast Masses With Doppler US

Enrollment
90 pts
Location
Turkey (Türkiye)
Sponsor
Ahmet Yesildag
View Trial →
NCT03730922
Recruiting

Delayed-immediate Versus Delayed Breast Reconstruction in Breast Cancer Patients With Mastectomy and Radiation Therapy

Enrollment
590 pts
Location
Denmark
Sponsor
Danish Breast Cancer Cooperati...
View Trial →
NCT07387445
Recruiting

Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.

Enrollment
40 pts
Location
United States
Sponsor
University of Illinois at Chic...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology